Akèy › Kansè Vezik ki pa envazif miskilè › Arkansas
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Arkansas
6 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan Arkansas.
Vil nan Arkansas
Tèks ofisyèl etid la (Anglè)
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Arkansas Urology, Little Rock
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06995677A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
- Arkansas Urology, Little Rock
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07309445Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Arkansas Urology, Little Rock
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05951179Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
- Arkansas Urology, Little Rock
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT07480356LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Arkansas Urology, Little Rock
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
- Arkansas Urology, Little Rock
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT05710848Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.